The results showed a correlation between low expression of p16 and poor PFS in patients with bladder cancer (HR = 2.18, 95% CI = 1.37~3.48, and P = 0.001), with low heterogeneity detected (I2 = 26.3%, P = 0.219). The gene discussed is CDKN2A; the disease is urinary bladder cancer.